Lv1
30 积分 2024-05-10 加入
Ivosidenib monotherapy in IDH1 mutated myelodysplastic neoplasm/syndrome
8天前
已完结
How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified?
9天前
已完结
Distinctive Molecular Risk Factors Between MDS and MDS/AML Defined by ICC
9天前
已完结
Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial
10天前
已完结
Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic Syndrome
10天前
已完结
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
10天前
已完结
A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions
10天前
已完结
Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database
12天前
已完结
Donor age and type in allogeneic haematopoietic stem cell transplantation: Strong effect in MDS, limited in AML
13天前
已完结
Clinical outcomes of patients with lower risk myelodysplastic syndrome from EUMDS registry eligible for transplantation: Implications for transplantation strategies
13天前
已完结
皖公网安备34019202002308
